FDA approved expanded pediatric age indication for Fluarix Quadrivalent influenza vaccine
On Jan. 11, 2018, the U.S. Food and Drug Administration (FDA) approved an expanded indication for the four-strain influenza vaccine Fluarix Quadrivalent (GlaxoSmithKline) to children as young as 6 months.
FLUARIX QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
Tags:
Source: U.S. Food and Drug Administration
Credit:
